Using a mouse xenograft model of non-small cell lung cancer (NSCLC), Xiang et al89 observed that a triple–drug combination (apatinib + bevacizumab (BEV) + cisplatin) suppressed angiogenesis and the formation of malignant pleural effusion (MPE) in NSCLC by down-regulating HIF-1α, VEGF, VEGFR-2, MEK1, and MMP-2 molecular signaling pathway proteins, and facilitated apoptosis of tumor cells in vivo, ultimately greatly prolonging the overall survival of tumor-bearing mice. This evidence concerns the gene MAP2K1 and neoplasm.